Introduction to Alecnib
Alecnib 150 mg is identified as a pharmaceutical product containing alectinib, a targeted anticancer medicine belonging to the anaplastic lymphoma kinase (ALK) inhibitor class. Alectinib is used to treat specified patients with ALK-positive non-small cell lung cancer (NSCLC).
The medicine works by interfering with abnormal molecular signals that contribute to cancer-cell growth and survival. Unlike conventional chemotherapy, which may affect many types of rapidly dividing cells, alectinib is designed to target a particular molecular abnormality associated with certain lung cancers.
The stated strength of Alecnib is 150 mg. Alectinib is available as a 150 mg oral capsule in its established reference formulation. The dosage form, composition and packaging of the specific Alecnib product should be confirmed using its official product documentation.
This page explains the generic medicine, therapeutic classification, medical purpose, clinical background, mechanism of action, recognized treatment settings and important safety considerations.
What Is Alectinib?
Alectinib is an oral targeted anticancer medicine classified as an ALK tyrosine kinase inhibitor.
It is designed to inhibit the activity of abnormal ALK proteins associated with certain cancers. ALK is a gene that produces a protein involved in cellular signaling. In some patients with lung cancer, a genetic rearrangement involving ALK results in an abnormal fusion protein.
This abnormal protein can remain continuously active and send signals that encourage cancer cells to multiply, survive and spread.
Alectinib blocks the activity of this protein and interferes with the molecular pathways involved in cancer progression.
The medicine is particularly important in the management of ALK-positive NSCLC, a molecularly defined subgroup of lung cancer.
Alectinib is not appropriate for all lung cancer patients. Its use requires evidence of the relevant ALK genetic alteration and an assessment by an oncology specialist.
Therapeutic Classification
Alectinib belongs to the following therapeutic and pharmacological categories:
| Classification | Description |
|---|---|
| Generic medicine | Alectinib |
| Therapeutic category | Antineoplastic medicine |
| Pharmacological class | ALK tyrosine kinase inhibitor |
| Drug type | Targeted cancer therapy |
| Molecular target | Anaplastic lymphoma kinase |
| Additional kinase activity | RET |
| Primary treatment area | ALK-positive NSCLC |
| Route | Oral administration |
| Stated Alecnib strength | 150 mg |
Tyrosine kinases are enzymes that transfer phosphate groups to proteins and participate in cellular communication. Some cancer cells depend on abnormal kinase activity to maintain growth and survival.
By inhibiting these abnormal signals, alectinib can interfere with the processes that support ALK-driven cancer.
What Does ALK-Positive Mean?
ALK-positive describes a cancer in which testing identifies an abnormal alteration involving the ALK gene.
In certain NSCLC cases, parts of the ALK gene become rearranged and join with another gene. This creates an abnormal fusion gene that produces an ALK fusion protein.
The resulting protein can activate signaling pathways even when normal cellular regulation would otherwise limit its activity.
This abnormal signaling may contribute to:
- Uncontrolled cancer-cell multiplication.
- Increased cancer-cell survival.
- Tumor development.
- Cancer progression.
- Spread of disease to other organs.
ALK-positive NSCLC represents a distinct molecular subtype of lung cancer. Identifying this alteration helps doctors determine whether an ALK-targeted medicine such as alectinib may be appropriate.
Medical Purpose of Alecnib
The medical purpose of Alecnib is associated with its stated active ingredient, alectinib.
Alectinib is used in specified treatment settings involving ALK-positive NSCLC.
Adjuvant treatment
Adjuvant treatment is given after the primary cancer has been surgically removed.
Some patients remain at risk of recurrence even after an operation. Additional treatment may be recommended to reduce that risk.
In the United States, alectinib is indicated as adjuvant treatment for adults following resection of qualifying ALK-positive NSCLC tumors measuring at least 4 cm or involving lymph nodes.
The prescribed duration for this reference-product indication is generally two years, unless the cancer recurs or unacceptable toxicity requires treatment to end earlier.
Metastatic disease
Metastatic NSCLC is lung cancer that has spread beyond its original location.
Alectinib is indicated for adults with ALK-positive metastatic NSCLC in the United States. Its purpose is to inhibit the abnormal ALK signaling responsible for supporting cancer-cell growth.
The treatment plan depends on molecular testing, disease characteristics, previous therapy and the patient’s overall health.
Development and Clinical Background
Alectinib was developed as a targeted medicine for cancers driven by abnormal ALK signaling.
The reference medicine Alecensa received its initial approval in the United States in 2015. Since then, alectinib has become an established treatment option for appropriately selected patients with ALK-positive NSCLC.
Clinical development evaluated its ability to inhibit ALK activity and its role in treating advanced disease.
The medicine has also been studied in earlier-stage treatment settings, including after surgical removal of qualifying lung cancers.
Its clinical role reflects the development of precision oncology, in which treatment selection increasingly considers the molecular characteristics of an individual’s cancer rather than relying exclusively on the location or appearance of a tumor.
The reference brand Alecensa is associated with Roche and Genentech. This historical and commercial information relates to the reference medicine and does not independently identify the manufacturer of Alecnib.
Mechanism of Action
Alectinib inhibits abnormal ALK tyrosine kinase activity.
The ALK fusion protein found in certain lung cancers can activate downstream signaling pathways that regulate cell growth, survival and proliferation.
Alectinib interferes with the kinase activity of this abnormal protein.
Its pharmacological activity includes:
ALK inhibition: Alectinib blocks the abnormal ALK signaling responsible for supporting the growth of ALK-dependent cancer cells.
Interference with cellular signaling: By inhibiting ALK, the medicine reduces activation of downstream pathways involved in cell proliferation and survival.
RET inhibition: Alectinib also has activity against RET, another receptor tyrosine kinase.
Central nervous system activity: Alectinib can penetrate the central nervous system, an important characteristic when managing ALK-positive lung cancer that may involve the brain.
The precise treatment response depends on the cancer’s biology and the patient’s individual clinical circumstances.
Available Strength and Product Information
Alecnib is identified on this website in the 150 mg strength.
| Product information | Details |
|---|---|
| Brand name | Alecnib |
| Active ingredient | Alectinib |
| Strength | 150 mg |
| Dosage form | Requires verification from the actual product |
| Therapeutic class | ALK inhibitor |
| Administration | Oral, subject to product verification |
| Reference brand | Alecensa |
| Alecnib manufacturer | Not independently verified |
| Product registration | Requires verification |
The 150 mg strength describes the amount of alectinib in a dosage unit. It does not automatically represent the complete daily treatment dose.
General Administration Information
Alectinib is administered orally according to a prescribed treatment schedule.
The established U.S. reference-product regimen for adults is 600 mg twice daily with food. The 150 mg capsules are combined to provide the prescribed amount.
Patients should follow their own prescription rather than calculating or changing their dose independently.
General administration considerations include:
- Take the medicine with food.
- Follow the prescribed morning and evening schedule.
- Swallow capsules whole.
- Do not open or dissolve the capsules.
- Do not take an extra dose after vomiting.
- If a dose is missed, continue with the next scheduled dose.
- Inform the healthcare professional about all other medicines being taken.
Dose adjustments may be necessary for significant adverse reactions or certain medical conditions.
Important Precautions
Alectinib requires careful clinical supervision.
Important precautions include:
- Liver-function abnormalities and possible liver injury.
- Interstitial lung disease and pneumonitis.
- Slow heart rate.
- Muscle pain and increased CPK levels.
- Hemolytic anemia.
- Severe kidney impairment.
- Elevated triglyceride levels and possible pancreatitis.
- Pregnancy-related risks.
- Potential interactions with other medicines.
Patients should attend recommended medical appointments and laboratory assessments throughout treatment.
Who Should Discuss Alectinib Carefully With a Doctor?
Before treatment, patients should disclose their medical history and current medicines.
Particular attention may be necessary for people with:
- Existing liver disease.
- Kidney impairment.
- Heart rhythm abnormalities.
- A history of significant muscle disorders.
- Previous anemia or blood disorders.
- Respiratory conditions.
- Pregnancy or plans to become pregnant.
- Breastfeeding considerations.
The treating healthcare professional will determine whether alectinib is suitable and what monitoring is necessary.
Alecnib and Its Reference Brand
Alecensa is an established reference brand containing alectinib.
Alecnib is the brand name identified for this website. The relationship between Alecnib and the reference product should not be overstated without appropriate documentation.
Although two products may contain the same active ingredient and stated strength, their manufacturers, inactive ingredients, manufacturing processes, packaging and regulatory authorizations may differ.
Product identity should therefore be established using the actual package and official documentation.
Conclusion
Alecnib 150 mg is identified as a product containing alectinib, a targeted ALK tyrosine kinase inhibitor used in specified patients with ALK-positive non-small cell lung cancer.
Alectinib works by blocking abnormal ALK signaling, helping interfere with the molecular processes that support cancer-cell growth and survival.
Understanding its therapeutic classification, medical purpose, molecular mechanism, administration requirements and safety profile is important when evaluating its role in cancer treatment.
All treatment decisions must be made by qualified healthcare professionals using the applicable prescribing information and the patient’s individual clinical findings.